Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoFuse in Lumbar Interbody Fusion
NCT00996073Phase 2Completed
- Sponsor
- Mesoblast Ltd
- Start
- Sep 2009
- Primary completion
- Jul 2012
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rexlemestrocel-l in degenerative disc disease (DDD) (3 arms), sponsored by Mesoblast Ltd. Primary endpoint: Overall Safety at 3 years. Started Sep 2009; status: completed.
02
Drugs
rexlemestrocel-l
03
Conditions
degenerative disc disease (DDD)
Beyond the preview
Go deeper on NCT00996073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00996073.